2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1677

Management of Severe Renal Disease in Anti-Neutrophil-Cytoplasmic-Antibodies Associated Vasculitis: Role of Rituximab and Plasma Exchange?
Abstract Number: 1265

Mandibular Involvement in SAPHO Syndrome: A Single-center Retrospective Study of 26 Patients
Abstract Number: 1033

Mass Cytometric Immunophenotyping Highlights a Dysregulated T cell-B Cell Axis in Patients with New-onset Lupus
Abstract Number: 35

Mass Cytometry Identifies Enhanced Histone H3 Citrullination and TNFα Production by CD14 Monocytes in Subjects At-Risk for Future Development of Rheumatoid Arthritis
Abstract Number: 99

Mass Cytometry Immunophenotyping of Synovial Fluid from Checkpoint Inhibitor Related Arthritis
Abstract Number: 461

Maximal Improvement in Fatigue Lags Behind Achievement of Sustained Remission in Early Rheumatoid Arthritis
Abstract Number: 2488

MDA Versus DAPSA: Applicability in a Real World
Abstract Number: 698

Measurement of Type I IFNα Production at the mRNA Level and Its Potential Use as a Biomarker in Systemic Lupus Erythematosus
Abstract Number: 266

Measuring Advanced/Extended Practice Roles in Arthritis and Musculoskeletal Care in Canada: Stand up and Be Counted Too (2)!
Abstract Number: 1970

Mechanism of Chondroprotective Effects of 4-Methylumbelliferone and 2-Deoxyglucose
Abstract Number: 1077

Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications
Abstract Number: 2208

Mediators of Bone Metabolism (DKK1, OPG, Sclerostin and RANKL) in a Cohort of Patients with Elderly-onset Arthritis
Abstract Number: 1134

Medicaid Spending (2013-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
Abstract Number: 1133

Medicare Spending (2012-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
Abstract Number: 2764

Medication Necessity and Concerns Beliefs Are Distinct, Interactive Predictors of Treatment Adherence in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].